These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17430148)

  • 1. The NMDA receptor as a therapeutic target in major depressive disorder.
    Pittenger C; Sanacora G; Krystal JH
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):101-15. PubMed ID: 17430148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
    Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
    Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc in the Glutamatergic Theory of Depression.
    Mlyniec K
    Curr Neuropharmacol; 2015; 13(4):505-13. PubMed ID: 26412070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate and depression: clinical and preclinical studies.
    Paul IA; Skolnick P
    Ann N Y Acad Sci; 2003 Nov; 1003():250-72. PubMed ID: 14684451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant effects of ketamine in depressed patients.
    Berman RM; Cappiello A; Anand A; Oren DA; Heninger GR; Charney DS; Krystal JH
    Biol Psychiatry; 2000 Feb; 47(4):351-4. PubMed ID: 10686270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for treating major depressive disorder.
    Dhir A
    Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
    Szakacs R; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate-based antidepressants: preclinical psychopharmacology.
    Pilc A; Wierońska JM; Skolnick P
    Biol Psychiatry; 2013 Jun; 73(12):1125-32. PubMed ID: 23453290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
    Kato T; Duman RS
    Pharmacol Biochem Behav; 2020 Jan; 188():172827. PubMed ID: 31733218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review.
    Petrie RX; Reid IC; Stewart CA
    Pharmacol Ther; 2000 Jul; 87(1):11-25. PubMed ID: 10924739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.